AstraZeneca pays out $425m in court settlement over heartburn drugs
AstraZeneca has paid out $425m (£352.37m) to settle lawsuits across two districts in the US that claim its heartburn medications,…
AstraZeneca
-
-
Filings signal: Despite Covid losses, pharma earnings are promising
Each week, Pharmaceutical Technology’s journalists pick out insights from company filings that highlight sentiments in our sector. These filings signals…
-
AstraZeneca vaccine and blood clots: the risks explained
AstraZeneca Vaccine and Blood Clots: Risks Explained In mid-March, a number of European countries paused their rollout of the AstraZeneca…
-
AstraZeneca and Merck obtain EMA orphan status for selumetinib
AstraZeneca and Merck (MSD) have secured the European Medicines Agency orphan designation for a MEK 1/2 inhibitor called selumetinib to…
-
AstraZeneca faces US DOJ probe for alleged funding of Iraqi terrorists
The US Department of Justice (DOJ) has reportedly launched an investigation into a lawsuit that alleges AstraZeneca bribed terrorists in…
-
AstraZeneca divests Atacand’s European rights for $210m
AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to German pharmaceutical…